FDA REMS
-
agranulocytosis, antipsychotics, clozapine, Drugs, early intervention, FDA REMS, Finnish registry, first episode psychosis, negative symptoms, Psychiatry, psychosis, relapse prevention, schizophrenia, treatment-resistant schizophreniaEarly Clozapine in Schizophrenia: 34% Lower Relapse Risk
Clozapine has been the most effective antipsychotic in schizophrenia for almost 40…
